Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viking Therapeutics (VKTX) Net Income (2016 - 2025)

Historic Net Income for Viking Therapeutics (VKTX) over the last 12 years, with Q4 2025 value amounting to -$157.7 million.

  • Viking Therapeutics' Net Income fell 34556.42% to -$157.7 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$359.6 million, marking a year-over-year decrease of 22700.01%. This contributed to the annual value of -$359.6 million for FY2025, which is 22700.01% down from last year.
  • Latest data reveals that Viking Therapeutics reported Net Income of -$157.7 million as of Q4 2025, which was down 34556.42% from -$90.8 million recorded in Q3 2025.
  • Over the past 5 years, Viking Therapeutics' Net Income peaked at -$12.4 million during Q4 2021, and registered a low of -$157.7 million during Q4 2025.
  • Moreover, its 5-year median value for Net Income was -$20.9 million (2022), whereas its average is -$34.0 million.
  • In the last 5 years, Viking Therapeutics' Net Income plummeted by 1044.42% in 2023 and then tumbled by 34556.42% in 2025.
  • Viking Therapeutics' Net Income (Quarter) stood at -$12.4 million in 2021, then crashed by 58.29% to -$19.6 million in 2022, then dropped by 25.72% to -$24.6 million in 2023, then crashed by 44.0% to -$35.4 million in 2024, then plummeted by 345.56% to -$157.7 million in 2025.
  • Its Net Income stands at -$157.7 million for Q4 2025, versus -$90.8 million for Q3 2025 and -$65.5 million for Q2 2025.